A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers
Clinical trial NCT02552953 · COMPLETED
Trial details
- NCT number
- NCT02552953
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-09-28
- Primary completion
- 2022-10-04
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.